The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

A multiomic analysis led by the IrsiCaixa AIDS Research Institute has uncovered genetic and immune mechanisms in some ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

Some people infected with HIV are teeming with virus, but don’t get sick. Their resistive powers probably come from a mix of ...

Fostemsavir plus optimized background therapy was associated with improvements in immune biomarkers among HTE patients with MDR HIV infection.

Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.

Among recipients with HIV, kidney transplantation from donors with HIV is noninferior to that from donors without HIV.

Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

The national HIV prevalence was 16. 3% among adults aged 15 years and older, translating to an estimated 7. 4 million adults ...

The following is a summary of “Infectious disease events in people with HIV receiving kidney transplantation: Analysis of the ...

The availability of such kidney transplants outside of the research setting could substantially improve organ availability ...